(Q44314885)

1 December 2017

A comparison of fibrosis progression in chronic liver diseases (English)

1 reference

1 December 2017

chronic liver disease

0 references

author

Thierry Poynard

1

1 reference

1 December 2017

4

1 reference

1 December 2017

14

1 reference

1 December 2017

Philippe Mathurin

2

0 references

Ching-Lung Lai

object named as

Ching-Lung Lai

3

0 references

author name string

Renée Poupon

5

1 reference

1 December 2017

Marie-Hélène Tainturier

6

1 reference

1 December 2017

Robert P Myers

7

1 reference

1 December 2017

Mona Muntenau

8

1 reference

1 December 2017

Vlad Ratziu

9

1 reference

1 December 2017

Michael Manns

10

1 reference

1 December 2017

Arndt Vogel

11

1 reference

1 December 2017

Frédérique Capron

12

1 reference

1 December 2017

Antonio Chedid

13

1 reference

1 December 2017

PANFIBROSIS Group

15

1 reference

1 December 2017

1 March 2003

1 reference

1 December 2017

Journal of Hepatology

1 reference

1 December 2017

38

1 reference

1 December 2017

3

1 reference

1 December 2017

257-265

1 reference

Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Trends of liver cirrhosis mortality in Europe, 1970-1989: age-period-cohort analysis and changing alcohol consumption

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Long-term survival in patients with hereditary hemochromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Cancer risk in primary biliary cirrhosis: a study in northern England

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Noninvasive diagnosis of hepatic fibrosis or cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Modeling the hepatitis C virus epidemic in France

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Estimating future hepatitis C morbidity, mortality, and costs in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Excess weight risk factor for alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

The Measurement of Observer Agreement for Categorical Data

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

The effect of age upon liver volume and apparent liver blood flow in healthy man.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Peroxisome Proliferator-activated Receptor α Activation Modulates Cellular Redox Status, Represses Nuclear Factor-κB Signaling, and Reduces Inflammatory Cytokine Production in Aging

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Sex and hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

Medical disorders of alcoholism.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900413-0

7 January 2021

10.1016/S0168-8278(02)00413-0

Identifiers

DOI

1 reference

1 December 2017

1 reference